Prosecution Insights
Last updated: April 19, 2026

Sanofi Pasteur

4 pending office actions

Portfolio Summary

4
Total Pending OAs
1
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18034242 Liposomes Containing TLR4 Agonist, Preparation and Uses Thereof SHOMER, ISAAC 1612 Final Rejection Apr 27, 2023
18016625 LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF ROZOF, TIMOTHY R 1625 Non-Final OA Jan 17, 2023
18077713 Human Cytomegalovirus Immunogenic Composition GILL, RACHEL B 1671 Non-Final OA Dec 08, 2022
17615989 METHOD FOR DETERMINING AT A CURRENT TIME POINT A PRESERVATION STATE OF ONE PRODUCT AND COMPUTER SYSTEM FOR CARRYING OUT SAID METHOD ANDERSON-FEARS, KEENAN NEIL 1687 Non-Final OA Dec 02, 2021

Managing Sanofi Pasteur's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month